Replicating anti-diabetic effects of bariatric surgery using small molecule
Metabolic surgery that involves gut repositioning leads to an immediate remission of diabetes and significant weight loss within a month. Diabetes remission after surgery is largely achieved by relieving hepatic insulin resistance and by reprogramming intestinal metabolism. Recently, we have identified a target gene that can be inhibited using a small molecule and regenerate the anti-diabetic effects of bariatric surgery - that is, lower glucose output from the liver and enhance glucose utilization in the intestine. Read more... |
Developing a first-in-class non-surgical alternative to treat rare fat disorders
Rare fat disorders such as Dercum’s disease and Familial Multiple Lipomatosis (FML) are characterized by the formation of subcutaneous fat deposits (lipomas). In case of Dercum’s, the lipomas are painful to the extent that pain killers are prescribed for daily management of the condition. The affected individuals often experience weight gain, depression, lethargy, and/or confusion. In both disorders, the condition can severely limit mobility and sometimes progress towards disfigurement. Currently, there are no FDA approved drugs to treat these conditions. At Nivarta, we are developing a subcutaneous injectable, NLM-0100, that has significant lipolytic activity and is capable of shrinking the size of lipomas. If approved by FDA, NLM-0100 will serve as a first-in-class non-surgical alternative to treat Dercum’s and FML. In addition, NLM-0100 is also suitable to treat NAFLD/NASH, submental fullness, lipedema, and lipomas in canine. Read more... |